Novartis’ Cosentyx approved in China to treat paediatric psoriasis
Cosentyx was previously approved in China for the treatment of moderate-to-severe plaque psoriasis and ankylosing spondylitis in adults
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
18 Aug 21
Cosentyx was previously approved in China for the treatment of moderate-to-severe plaque psoriasis and ankylosing spondylitis in adults
18 Aug 21
Spikevax vaccine, previously called Covid-19 Vaccine Moderna, was already approved in the UK, for active immunisation in adults…
17 Aug 21
Initial data was submitted from Phase 1 of the Phase 1/2/3 clinical trial programme, evaluating the third dose…
16 Aug 21
The company is working to optimise production of Welireg, which is an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor,…
16 Aug 21
The immunogenicity of Ticovac was assessed in clinical studies across the population aged between 1 to 15 years…
13 Aug 21
Durezol is a topical corticosteroid, indicated for inflammation and pain associated with ocular surgery, and for endogenous anterior…
12 Aug 21
The FDA approval is based on Phase 3 CLEAR/KEYNOTE-581 trial, in which Keytruda plus Lenvima combination was superior…
11 Aug 21
The MHRA approval allows the use of Epidyolex in England, Wales and Scotland, along with all 27 countries…
10 Aug 21
Forxiga is an oral, once-daily sodium-glucose cotransporter 2 (SGLT2) inhibitor, with potential in preventing and delaying cardiorenal disease,…
09 Aug 21
The FDA approval is based on positive Phase 3 data showing improvements in key disease burden measures and…